# A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

> **NCT00695396** · PHASE3 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 25 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Anemia

## Interventions

- **DRUG:** Placebo
- **DRUG:** Epoetin alfa
- **DRUG:** Placebo
- **DRUG:** Epoetin alfa

## Key facts

- **NCT ID:** NCT00695396
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** The study was stopped due to low subject enrollment. No safety issue or other concern factored into this decision.
- **Last updated:** 2012-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00695396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00695396, "A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00695396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*